Vor Biopharma, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US9290331084
USD
8.33
0.8 (10.62%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

435.61 k

Shareholding (Mar 2025)

FII

2.02%

Held by 29 FIIs

DII

81.3%

Held by 19 DIIs

Promoter

6.76%

How big is Vor Biopharma, Inc.?

22-Jun-2025

As of Jun 18, Vor Biopharma, Inc. has a market capitalization of 25.77 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -118.60 million over the latest four quarters.

Market Cap: As of Jun 18, Vor Biopharma, Inc. has a market capitalization of 25.77 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Vor Biopharma, Inc. reported net sales of 0.00 million and a net profit of -118.60 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 96.66 million and total assets of 153.02 million.

Read More

What does Vor Biopharma, Inc. do?

22-Jun-2025

Vor Biopharma, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $32 million and a market cap of $25.77 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a return on equity of -179.50%.

Overview: <BR>Vor Biopharma, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -32 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 25.77 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.84 <BR>Return on Equity: -179.50% <BR>Price to Book: 0.39<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Vor Biopharma, Inc. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, Vor Biopharma, Inc. has a mildly bullish trend influenced by daily moving averages and monthly Bollinger Bands, despite short-term weakness indicated by the weekly MACD and RSI, and while it has underperformed the S&P 500 recently, it has outperformed year-to-date.

As of 3 September 2025, the technical trend for Vor Biopharma, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by daily moving averages and monthly Bollinger Bands showing bullish signals. However, the weekly MACD and RSI indicate a mildly bearish trend, suggesting some short-term weakness. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -16.25% and -25.49% respectively, while it has outperformed on a year-to-date basis with a return of 36.94% compared to the S&P 500's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 251 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.13

stock-summary
Return on Equity

24.21%

stock-summary
Price to Book

-0.17

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-1,574 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-79.18%
0%
-79.18%
6 Months
87.95%
0%
87.95%
1 Year
-54.02%
0%
-54.02%
2 Years
-78.31%
0%
-78.31%
3 Years
68.28%
0%
68.28%
4 Years
-96.7%
0%
-96.7%
5 Years
0%
0%
0.0%

Vor Biopharma, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-268.53%
EBIT to Interest (avg)
-91.69
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.84
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
61.34%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.42
EV to EBIT
0.23
EV to EBITDA
0.23
EV to Capital Employed
-2.70
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-179.50%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 21 Schemes (9.86%)

Foreign Institutions

Held by 29 Foreign Institutions (2.02%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -5,560.79% vs 7.33% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-272.20",
          "val2": "-28.10",
          "chgp": "-868.68%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1,299.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1,573.70",
          "val2": "-27.80",
          "chgp": "-5,560.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.85% vs -28.01% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-117.70",
          "val2": "-122.50",
          "chgp": "3.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-116.90",
          "val2": "-117.90",
          "chgp": "0.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-272.20
-28.10
-868.68%
Interest
0.00
0.00
Exceptional Items
-1,299.90
0.00
Consolidate Net Profit
-1,573.70
-27.80
-5,560.79%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -5,560.79% vs 7.33% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-117.70
-122.50
3.92%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-116.90
-117.90
0.85%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 0.85% vs -28.01% in Dec 2023

stock-summaryCompany CV
About Vor Biopharma, Inc. stock-summary
stock-summary
Vor Biopharma, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available